Docoh
Loading...

MNKKQ Mallinckrodt

Mallinckrodt Pharmaceuticals is an Irish–tax registered manufacturer of specialty pharmaceuticals , generic drugs and imaging agents. In 2017 it generated 90% of sales from the U.S. healthcare system. While Mallinckrodt is headquartered in Ireland for tax purposes, its operational headquarters are in the U.S. Mallinckrodt's 2013 tax inversion to Ireland drew controversy when it was shown Acthar, was Medicaid's most expensive drug. Mallinckrodt acquires , manufactures, and distributes products used in diagnostic procedures and in the treatment of pain and related conditions. This includes the acquisition, manufacture, and distribution of specialty pharmaceuticals, active pharmaceutical ingredients, contrast products, and radiopharmaceuticals. The company employed 5,500 and had net sales of $3.2 billion in 2017; of which $2.9 billion was from the U.S. healthcare system.

Company profile

Ticker
MNKKQ, MNKKQ
Exchange
CEO
Mark Trudeau
Employees
Location
Fiscal year end
SEC CIK
Subsidiaries
Acthar IP Unlimited Company • Cache Holdings Limited • Carnforth Limited • Dritte CORSA Verwaltungsgesellschaft GmbH • Ikaria Australia Pty Ltd • Ikaria Canada Inc. • IMC Exploration Company • Infacare Pharmaceutical Corporation • INO Therapeutics LLC • Ludlow LLC ...
IRS number
981088325

MNKKQ stock data

(
)

Calendar

3 Aug 21
18 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
5 Aug 21 Norton David Y Ordinary Shares Sell Dispose S No No 0.2626 5,080 1.33K 0
5 Aug 21 O'Neill Hugh M. Ordinary Shares Sell Dispose S No No 0.2558 2,100 537.18 76,856
2 Apr 21 Schaefer Kathy A Ordinary Shares Payment of exercise Dispose F No No 0.38 398 151.24 22,934
1 Apr 21 Schaefer Kathy A Ordinary Shares Payment of exercise Dispose F No No 0.38 277 105.26 23,332
12 Mar 21 Carroll J Martin Ordinary Shares Sell Dispose S Yes No 0.4007 31,398 12.58K 0
12 Mar 21 Carroll J Martin Ordinary Shares Sell Dispose S No No 0.4007 10,667 4.27K 0
12 Mar 21 Paya Carlos V Ordinary Shares Sell Dispose S No No 0.4042 16,614 6.72K 0

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

8.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 12 18 -33.3%
Opened positions 4 17 -76.5%
Closed positions 10 0 NEW
Increased positions 0 0
Reduced positions 1 0 NEW
13F shares
Current Prev Q Change
Total value 277K 333K -16.8%
Total shares 7.22M 7M +3.1%
Total puts 0 0
Total calls 0 0
Total put/call ratio

Financial report summary

?
Management Discussion
  • This report contains certain financial measures, including net sales, gross profit, gross profit margin, SG&A expenses as a percentage of net sales and research and development ("R&D") expenses as a percentage of net sales, which exclude the one-time charge related to the Medicaid lawsuit that is included as a component of net sales.
  • We have provided these measures because they are used by management to evaluate our operating performance. In addition, we believe that they will be used by certain investors to measure Mallinckrodt's operating results. Management believes that presenting these measures provides useful information about our performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. These measures should be considered supplemental to and not a substitute for financial information prepared in accordance with accounting principles generally accepted in the U.S. ("GAAP").
  • Because these measures exclude the effect of items that will increase or decrease our reported results of operations, management strongly encourages investors to review our unaudited condensed consolidated financial statements and this report in its entirety. A reconciliation of certain of these financial measures to the most directly comparable GAAP financial measures is included herein.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: adjourned, amortizable, answered, BLA, Contemporaneously, contest, earliest, environment, Frank, graft, GvHD, host, Johnson, Luxembourg, mailed, mandate, Michael, predicated, premature, quality, rehearing, seal, solid, Strobl, Switzerland, tandem, transplant
Removed: adapting, advocacy, average, consulting, distributor, doctor, donating, emergency, experience, fight, funding, immunosuppressed, inclusion, inhaled, instructed, located, medically, noted, partnering, payroll, PPE, produce, prospective, protective, sensitive, submit, surgical, temporary, therapeutic, trained, travel, volunteer, yielded